Under construction – not a live service
Sign in

NCT05090566TerminatedPhase 2

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA

Source: ClinicalTrials.gov · Last updated 24 Apr 2026

Reason given: A business decision was made by Pfizer to terminate the study and not proceed with the Phase 2 expansion of this study. The reason for study termination is not due to any safety concerns or requests from regulatory authorities.

Brief summary (registry, in English)

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Status (registry)
Terminated
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
46 (actual)
First submitted
8 Oct 2021
Start date
27 Oct 2021
Primary completion date
13 Feb 2025
Lead sponsor
Pfizer
NCT number
NCT05090566
EudraCT number
2021-003885-11

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Stem cell transplant with 12 weeks prior to enrollment, or active GVHD
  • Impaired cardiovascular function or clinically significant cardiovascular diseases within 6 months prior to enrollment
  • Previous administration with an investigational drug within 30 days or 5 half-lives preceding the first dose of study treatment (whichever is longer)
  • Sub-Study A Only: Previous treatment with BCMA bispecific antibody
  • Sub-Study B Only: Previous treatment with BCMA directed therapy

Other illness

  • POEMS syndrome
  • Any active uncontrolled bacterial, fungal, or viral infection

Other

  • Active plasma cell leukemia
  • Amyloidosis

Who the study is looking for

  • Relapsed/refractory multiple myeloma with at least 3 prior lines of therapy
  • Refractory to at least one IMiD, one proteasome inhibitor, and one anti-CD38 antibody
  • Measurable disease defined by at least one of the following:
    • Serum M-protein >/= 0.5 g/dL by SPEP
    • Urinary M-protein excretion >/= 200 mg/24 hours by UPEP
    • Serum immunoglobulin FLC >/= 10 mg/dL (>/= 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda FLC ratio
  • ECOG performance status 0 -1
  • Resolved acute effects of any prior therapy to baseline severity or CTCAE Grade </= 1

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (24)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Arthur J.E. Child Comprehensive Cancer CentreCalgaryCanadaUnknown status
The Ottawa Hospital - General CampusOttawaCanadaUnknown status
Princess Margaret Cancer CentreTorontoCanadaUnknown status
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (Also Imaging Facility)BaltimoreUnited StatesUnknown status
OIDS, The Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsBaltimoreUnited StatesUnknown status
The Johns Hopkins University School of MedicineBaltimoreUnited StatesUnknown status
Beverly Hills Cancer CenterBeverly HillsUnited StatesUnknown status
Massachusetts General HospitalBostonUnited StatesUnknown status
Beth Israel Deaconess Medical CenterBostonUnited StatesUnknown status
University of MiamiCoral GablesUnited StatesUnknown status
Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical CenterCoral GablesUnited StatesUnknown status
Sylvester Comprehensive Cancer Center- Deerfield BeachDeerfield BeachUnited StatesUnknown status
Clinical Research AdvisorsEncinoUnited StatesUnknown status
Banner Gateway Medical PavilionGilbertUnited StatesUnknown status
Banner MD Anderson Cancer CenterGilbertUnited StatesUnknown status
Banner Gateway Medical CenterGilbertUnited StatesUnknown status
Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute (SOCCI)Los AngelesUnited StatesUnknown status
Clinical Research AdvisorsLos AngelesUnited StatesUnknown status
Cedars-Sinai Medical CenterLos AngelesUnited StatesUnknown status
Cedars Sinai Medical Center Oncology IDS Pharmacy Attn:Suwicha Limvorasak ,PharmaDLos AngelesUnited StatesUnknown status
Sylvester Comprehensive Cancer Center*MiamiUnited StatesUnknown status
UHealth TowerMiamiUnited StatesUnknown status
Banner Health d.b.a. Banner MD Anderson Cancer CenterPhoenixUnited StatesUnknown status
Cedars-Sinai TarzanaTarzanaUnited StatesUnknown status

Are you the coordinator? Confirm the details

This page is information, not medical advice. Discuss any trial with your doctor.